Abstract: A preventive or therapeutic agent for glaucoma or ocular hypertension includes a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate with one or more other preventive or therapeutic drugs for glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.

Abstract: A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.

Abstract: An object of the present invention is to provide an antibody having significantly high affinity for VEGF compared to the prior art. The present invention provides a monoclonal antibody against VEGF, which binds to a vascular endothelial growth factor (VEGF) with a dissociation constant of 1×10?11 mol/L or less.

Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.

Abstract: A method of delivering a dose from a single dose syringe includes applying a user input to a rotational component of a plunger rod assembly that is engaged with a plunger rod of the plunger rod assembly to advance a plunger seal in a direction parallel to an axis of rotation of the rotational component from an initial position towards a start of dose delivery position, and upon disengagement of the rotational component from the plunger rod, applying an axial user input to the plunger rod of the plunger rod assembly to advance the plunger seal from the start of dose delivery position to a completion of dose delivery position to deliver the dose, wherein the completion of dose delivery position is defined by abutment between the plunger rod and a housing of the plunger rod assembly.

Abstract: The present disclosure provides an agent for treating or preventing an eye disease such as presbyopia, comprising, as an active ingredient, a sulfur-containing compound having a specified structure.

Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.

Abstract: The purpose of the present invention is to identify a drug formulation for the treatment or prevention of glaucoma or ocular hypertension, wherein the drug formulation exhibits an effect in patients with drug-refractory glaucoma or ocular hypertension. Sepetaprost is expected to exhibit an excellent intraocular pressure-lowering action in patients with otherwise drug-refractory glaucoma or ocular hypertension. The drug formulation according to the present invention containing sepetaprost as an active ingredient is therefore useful as a drug formulation that can treat or prevent glaucoma or ocular hypertension in patients with otherwise drug-refractory glaucoma or ocular hypertension.

Abstract: The present invention aims to find a pharmaceutical preparation which treats or prevents glaucoma or ocular hypertension and is effective for patients with inadequate efficacies of glaucoma or ocular hypertension therapeutic agents. It has been found that omidenepag, an ester thereof, or a salt thereof has an excellent intraocular pressure lowering efficacy on patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents. Therefore, the omidenepag, the ester thereof, or the salt thereof of the present invention is useful as a pharmaceutical preparation which can treat or prevent glaucoma or ocular hypertension even in patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents.

Abstract: According to some embodiments, a syringe may include a barrel; a delivery conduit; a plunger seal disposed within the barrel; and a plunger rod assembly affixed to an end of the barrel, the plunger rod assembly including a first plunger rod component comprising a first linear gear, a second plunger rod component disposed at least partially in the barrel and engaged with the plunger seal, wherein the second plunger rod component comprises a second linear gear, a first rotational gear having a plurality of gear teeth for engaging the first linear gear, and a second rotational gear having a second plurality of gear teeth for engaging the second linear gear, wherein the first rotational gear is coupled to the second rotational gear such that translation of the first plunger rod component causes translation of the second plunger rod component.

Abstract: A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.

Abstract: The present invention aims to find a pharmaceutical preparation which treats or prevents glaucoma or ocular hypertension and is effective for patients with inadequate efficacies of glaucoma or ocular hypertension therapeutic agents. It has been found that omidenepag, an ester thereof, or a salt thereof has an excellent intraocular pressure lowering efficacy on patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents. Therefore, the omidenepag, the ester thereof, or the salt thereof of the present invention is useful as a pharmaceutical preparation which can treat or prevent glaucoma or ocular hypertension even in patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents.

Abstract: The present invention relates to an ophthalmic aqueous composition containing a silver salt, and filled in a container made of a polyester-based resin, or a container made of a polyolefin-based resin excluding polypropylene. Besides, the present invention also relates to an ophthalmic preservative containing a silver salt, and filled in a container made of a polyester-based resin or a container made of a polyolefin-based resin excluding polypropylene, and a method for imparting, to an ophthalmic aqueous composition, preservative efficacy satisfying a criterion of Preservatives-Effectiveness Tests of The Japanese Pharmacopoeia, including adding a silver salt to the ophthalmic aqueous composition, and filling the ophthalmic aqueous composition in a container made of a polyester-based resin or a container made of a polyolefin-based resin excluding polypropylene.

Abstract: The present invention relates to an agent for preventing myopia, treating myopia, and/or preventing myopia progression, comprising tiotropium as an active ingredient.

Abstract: A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.

Abstract: The purpose of the present invention is to provide an aqueous suspension composition comprising poorly water-soluble sirolimus or a salt thereof for ophthalmology, in particular, used for topical administration, such as a less invasive eye drop. The present invention is an ophthalmic aqueous suspension composition comprising sirolimus or a salt thereof and a surfactant, wherein the aqueous suspension composition has a pH of 4 to 6.

Abstract: The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to the use of valproic acid for reducing post-operative scarring following a glaucoma surgery. In one embodiment, the glaucoma surgery is glaucoma filtering surgery, which comprises creating a subconjunctival bleb. In another embodiment, the glaucoma surgery is minimally invasive glaucoma surgery (MIGS), which comprises implanting a glaucoma tube shunt under a subconjunctival space.

Abstract: Described is a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. By combining sepetaprost and a Rho-associated coiled-coil containing protein kinase inhibitor(s), an intraocular pressure lowering action is enhanced as compared with the case where each drug is used alone. As the form of administration, they may be administered concomitantly or may be administered as a combination drug.

Abstract: Described is a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. By combining sepetaprost and a Rho-associated coiled-coil containing protein kinase inhibitor(s), an intraocular pressure lowering action is enhanced as compared with the case where each drug is used alone. As the form of administration, they may be administered concomitantly or may be administered as a combination drug.